Overview
- Features chapters authored by a diverse array of established, internationally known and up-coming investigators including members of the NCI-funded Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC)
- The book will guide readers through increasing the technical power of radiation therapy while safely increasing local control for solid tumors, improving survival outcomes and cure rates
- Readers will gain a comprehensive and thorough understanding of radiosensitizer development and usage
Part of the book series: Cancer Drug Discovery and Development (CDD&D)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (13 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
Molecular Targeted Radiosensitizers: Opportunities and Challenges provides the reader with a comprehensive review of key pre-clinical research components required to identify effective radiosensitizing drugs. The book features discussions on the mechanisms and markers of clinical radioresistance, pre-clinical screening of targeted radiosensitizers, 3D radiation biology for studying radiosensitizers, in vivo determinations of local tumor control, genetically engineered mouse models for studying radiosensitizers, targeting the DNA damage response for radiosensitization, targeting tumor metabolism to overcome radioresistance, radiosensitizers in the era of immuno-oncology, and more. Additionally, the book features discussions on high-throughput drug screening, predictive biomarkers, pre-clinical tumor models, and the influence of the tumor microenvironment and the immune system, with a specific focus on the challenges radiation oncologists and medical oncologists currently face in testing radiosensitizers in human cancers.
Edited by two acclaimed experts in radiation biology and radiosensitizers, with thirteen chapters contributed by experts, this new volume presents an in-depth look at current developments within a rapidly moving field, with a look at where the field will be heading and providing comprehensive insight into the framework of targeted radiosensitzer development. Essential reading for investigators in cancer research and radiation biology.
Editors and Affiliations
About the editors
Henning Willers, M.D., is an Associate Professor of Radiation Oncology at Harvard Medical School and an Associate Radiation Oncologist in the Department of Radiation Oncology at Massachusetts General Hospital. He is also the Director of the Thoracic Radiation Oncology Program at Massachusetts General Hospital. As a clinician-scientist, Dr. Willers’ clinical efforts have focused on improving treatment outcomes for patients with lung cancer. His basic and translational research activities are directed at elucidating how lung cancers respond to radiation and radiosensitizing drugs, and specifically seeking to identify the signaling pathways that contribute to the radioresistance of KRAS-mutant lung adenocarcinoma. Dr. Willers’ lab also studies the DNA repair pathways that are increasingly recognized to be altered in lung cancer and other cancer types. The goal of these studies is to establish genomic as well as functional protein biomarkers that will allow clinicians to identify patients whose tumors will exhibit increased sensitivity to specific DNA damaging treatments, including proton beam radiation and PARP inhibitors.
Iris Eke is currently a researcher at Stanford University. She earned her M.D. at the Technical University Munich, Germany. During her Ph.D. in Experimental Radiation Oncology at the Technical University Dresden, Germany, she focused on the innovative concept to target cell-extracellular matrix interactions to overcome radio- and chemoresistance and elucidated several new mechanistic insights. At the National Cancer Institute, National Institute of Health, Dr. Eke studied the mechanisms of tumor adaptation after multifractionated radiotherapy with the goal to identify novel potential drug therapy targets involving radiation-induced target activation and DNA repair.
Bibliographic Information
Book Title: Molecular Targeted Radiosensitizers
Book Subtitle: Opportunities and Challenges
Editors: Henning Willers, Iris Eke
Series Title: Cancer Drug Discovery and Development
DOI: https://doi.org/10.1007/978-3-030-49701-9
Publisher: Humana Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Nature Switzerland AG 2020
Hardcover ISBN: 978-3-030-49700-2Published: 11 August 2020
Softcover ISBN: 978-3-030-49703-3Published: 12 August 2021
eBook ISBN: 978-3-030-49701-9Published: 10 August 2020
Series ISSN: 2196-9906
Series E-ISSN: 2196-9914
Edition Number: 1
Number of Pages: XI, 364
Number of Illustrations: 4 b/w illustrations, 38 illustrations in colour
Topics: Cancer Research, Radiotherapy, Pharmacology/Toxicology